
A dual GIP and GLP-1 receptor agonist that blocks cravings, slows digestion, and helps you get full sooner and stay full longer.
No Insurance Required
Ships From USA Pharmacy
Free Medical Consultation
Syringes Included
No Subscription Required
Licensed Provider
Licensed Pharmacy
HIPAA Compliant
LegitScript Certified
Individual results may vary. Benefits described are based on clinical and pharmacological evidence and do not constitute a guarantee of treatment outcomes. All treatment requires evaluation and approval by a licensed provider.
Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. Engaging both receptors simultaneously produces weight loss and metabolic improvements that exceed what GLP-1 agonism alone can achieve.
Relative potency across six metabolic domains — showing where dual agonism outperforms GLP-1 monotherapy and where the mechanisms converge.
Both compounds are dosed once weekly. Full clinical effect develops over 8–20 weeks of dose escalation.
Six independent metabolic pathways engaged simultaneously — producing outcomes no single-receptor compound can replicate.




Yes. Tirzepatide is a compounded prescription medication available only pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, medical intake, and provider evaluation are required before dispensing to confirm clinical suitability, screen for contraindications, and establish an individualized titration plan.
The most common side effects are gastrointestinal and occur most frequently during dose escalation — they include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. Most patients find these effects diminish as the body adjusts to each dose level. Injection site reactions including mild redness, swelling, or transient discomfort may also occur. Seek prompt medical attention for severe or persistent abdominal pain or any symptoms suggestive of pancreatitis. Report all side effects to your provider.
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). It is not appropriate for patients with known hypersensitivity to tirzepatide or any component of the formulation, those with a history of serious pancreatitis, severe gastroparesis, or significant gastrointestinal disorders. Patients with severe renal impairment or serious hepatic dysfunction require individualized provider assessment. This medication is contraindicated during pregnancy.
Patients using insulin or sulfonylureas concurrently face an elevated risk of hypoglycemia, and dose adjustments of those agents are often required when Tirzepatide is initiated. Tirzepatide's gastric-emptying-slowing effect can delay absorption of orally administered medications including oral contraceptives and thyroid hormone, potentially affecting their clinical effectiveness. Patients on warfarin may need more frequent INR monitoring. Always provide a complete medication list to your provider before beginning treatment
Patients with a personal or family history of thyroid cancer or MEN2 must not use Tirzepatide. Those with type 1 diabetes, a history of pancreatitis, or significant gastrointestinal disorders require careful individualized evaluation. Patients with cardiovascular disease, hypertension, or significant renal or hepatic impairment can often be treated but require close provider monitoring. Your provider requires a complete medical history before prescribing and will determine whether Tirzepatide is appropriate for your specific health profile.
Licensed Provider
Licensed Pharmacy
HIPAA Compliant
LegitScript Certified

© 2026, Skinny Rich Shot®
text (323)-283-9219
638 1/2 N. Robertson Blvd, West Hollywood, CA 90069
Available in select U.S. states. Eligibility is determined by the provider. Compounded semaglutide and tirzepatide are not FDA-approved for weight loss. It is prescribed only when deemed medically appropriate by a licensed provider after review. Individual results vary significantly based on factors like adherence, diet, exercise, and health status. No guarantees of weight loss. GLP-1 medications like semaglutide may increase the risk of thyroid C-cell tumors based on animal studies; human risk is not confirmed. Services provided by licensed physicians/nurse practitioners in states served, e.g., CA, FL, and others, via telemedicine. Check your state's telemedicine laws. We prioritize your privacy and comply with HIPAA regulations for protected health information. Must be 18 or older.